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Introduction
As a result of the Global Polio Eradication Initiative, po-
liomyelitis has been successfully controlled and elimi-
nated in most developed countries by the systematic use
of vaccines. The most widely used in the last 50 years
has been the Sabin live attenuated oral poliovirus vac-
cine (OPV). The number of children paralyzed by the
disease has fallen from over 350,000 in 1988 to as few
as 1,900 in 2003; the number of countries where the dis-
ease is endemic has dropped from 127 or more to 7 re-
spectively between 1988 and the end of 2001 [1].
On 21 June 2002, the European Regional Commission
for the Certification of the Eradication of Poliomyelitis
certified that the European Region is free of indigenous
wild polioviruses [2].
In Italy, mass vaccination with OPV began in 1964 and
became compulsory in 1966; it soon led to a marked
downward trend in poliomyelitis morbidity; the last
cases of paralytic poliomyelitis in the early Eighties
were only vaccine-associated or imported from endem-
ic areas [3, 4].
Italy became polio-free from around the Eighties as a
result of high immunization coverage with routine ser-
vices and good-quality surveillance [5].
Wild poliomyelitis is still endemic in some undevel-
oped areas of the world, however, especially where it
is more difficult to reach people for religious, politi-
cal and geographical reasons. There is increasing mi-
gration from developed countries, with a consequent
risk of wild poliovirus strains being imported and cir-
culated [6-10].
Although the risk of acquiring poliomyelitis is minimal
in Italy, it may be important to know the prevalence of
polio-neutralizing antibodies in our geographical area
today, given the immigration problems and with a view
to achieving the goal of suspending vaccination now
that polio has been declared eradicated.
The aim of this study was to assess the current preva-
lence of neutralizing antibodies in two population
groups, i.e. in recently-immunized children and in el-
derly people who had never been vaccinated.
Methods
During the study period, 511 healthy subjects were ex-
amined. They were all resident in the Veneto Region
and were consecutively enrolled at a laboratory for
clinical analyses in one of the Region’s public hospi-
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Introduction. Italy and Europe were declared polio-free in June
2002, but increasing migration, even from undeveloped coun-
tries where polio still exists, may lead to a come-back of cir-
culating poliovirus (PV) and infection in previously polio-free
areas. It is consequently advisable to continue to monitor the
immunity of the population in polio-free areas. The aim of this
study was to assess the current prevalence of neutralizing anti-
bodies in recently-immunized children and in elderly people who
were never vaccinated.
Methods. Sera from 511 healthy subjects resident in the Veneto
Region were examined to assay their antibody titer for PV 1, 2
and 3, using the microneutralization test. Data were analyzed
by chi-squared test, Student’s t-test and linear regression analy-
sis, using EPI-Info 2000 supplied by the Centers for Disease
Control and Prevention (Atlanta, GA, USA).
Results. Neutralizing antibodies in group A (231 subjects aged
1-17 years) showed significantly higher geometric mean titers
(GMTs) than in group B (280 subjects aged 65-100 years) for
all three PV serotypes (P < 0.001). Nobody simultaneously
lacked neutralizing antibodies for all three serotypes. There
were no difference between the two groups in terms of
male/female GMTs for the three PV. Antibodies decreased with
time since vaccination, but the difference was only significant
for PV 3. GMTs were lower in the elderly, with no significant
difference among the three PV.
Discussion. The population examined showed a good level of
protection against the three PV strains: both groups A (vacci-
nated) and B (naturally immunized) revealed a valid immunity
to poliovirus.
Conclusion. Immunization programs and immunity status pop-
ulation screening are still advisable until polio has been world-
wide eradicated.
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tals. Blood specimens were drawn consecutively dur-
ing routine tests for health check-ups.
The subjects were grouped according to age: Group A:
subjects aged 1-17 years; Group B: subjects aged 65-
100 years.
All subjects, or the parents of children, were informed
about the study and consent was obtained from each
participant.
Venous blood samples were drawn from each subject at
the time of enrolment and the sera obtained were stored
at - 20 °C until they were tested in batches.
A microneutralization test was used to evaluate the
serum titer of poliovirus 1, 2 and 3 antibodies. Serum
samples were complement-inactivated at 56 °C for 30
minutes and diluted from 1:2 to 1:512. They were then
placed in contact with 100 TCID50 of the three types of
Sabin attenuated polioviruses (type 1: L Sc2ab strain-,
type 2: P712ch2ab, type 3: Leon 12alb). After
overnight incubation at 4 °C, a suspension of freshly
trypsinized Vero cells (approximately 105/ml) was
added to each well containing the serum/virus mixture,
and the solution was incubated at 36 °C in a 5% CO2 in-
cubator. The final test reading was carried out after 6
days. The 50% endpoint value was used as the serum
titer, and geometrical mean titers (GMTs) were com-
puted by log10 of reciprocal antibody titers ≥ 1:2. Titers
≥ 1:2 were considered positive.
Data were analyzed using the chi-squared test, Stu-
dent’s t-test for unpaired data and linear regression
analysis, as appropriate. Analyses were performed us-
ing EPI-Info 2000 supplied by the Centers for Disease
Control and Prevention (Atlanta, GA, USA).
Results
The population studied included 511 people grouped
by age:
• Group A: 231 subjects aged 1-17 years (mean age
8.0 ± 4.1 years), 120 (51.9%) males and 111
(48.1%) females, who had been vaccinated with
oral poliovirus vaccines (OPV) according to the
Italian compulsory vaccination schedule;
• Group B: 280 subjects aged 65-100 years (mean age
83.4 ± 9.1 years), 68 (24.3%) males and 212
(75.7%) females, none of whom had received any
doses of polio vaccine during their life.
Table I shows the prevalence of neutralizing antibodies
according to serum titer, group and poliovirus type. The
GMTs were significantly higher in the younger group
than in the elderly for all serotypes (p < 0.001). No sub-
jects simultaneously lacked neutralizing antibodies for
all three polioviruses. Only poliovirus type 1 revealed
any seronegativity: in a 5 year-old female in Group A
and in a 65-year-old male and an 85-year-old female in
group B.
The GMTs for polioviruses 1, 2 and 3 did not differ sig-
nificantly between males and females in either group
(Tab. II).
The GMTs of neutralizing antibodies in group A
showed a constant decline after vaccination. This de-
cline was smaller for poliovirus 1 and greater for po-
lioviruses 2 and 3. Linear regression analysis showed a
significant decrease only for serotype 3 (r = 0.958; p =
0.042).
Group B had lower GMTs and the declining trend of
the three serotypes showed no significant differences,
while it revealed a slight increase beyond 89 years old
(Fig. 1).
Discussion
This study was conducted to check on the humoral im-
munity status in two opposite age brackets,
children/adolescents and the elderly, a few years since
Tab. I. Neutralizing antibody prevalence according to serum titer, group and type of poliovirus.
serum titer group A (children) group B (elderly)
poliovirus poliovirus
type 1 type 2 type 3 type 1 type 2 type 3
n (%) n (%) n (%) n (%) n (%) n (%)
negative 1 (0.4) 0 (0.0) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0)
2 1 (0.4) 1 (0.4) 1 (0.4) 2 (0.7) 4 (1.4) 3 (1.1)
4 3 (1.3) 2 (0.9) 0 (0.0) 19 (6.8) 19 (6.8) 17 (6.1)
8 5 (2.2) 4 (1.7) 4 (1.7) 26 (9.3) 28 (10.0) 37 (13.2)
16 8 (3.5) 3 (1.3) 3 (1.3) 32 (11.4) 37 (13.2) 29 (10.4)
32 5 (2.2) 13 (5.6) 8 (3.5) 26 (9.3) 35 (12.5) 24 (8.6)
64 6 (2.6) 18 (7.8) 25 (10.8) 33 (11.8) 31 (11.1) 36 (12.9)
128 23 (10.0) 50 (21.6) 51 (22.1) 38 (13.6) 50 (17.9) 47 (16.8)
256 44 (19.0) 71 (30.7) 73 (31.6) 67 (23.9) 40 (14.3) 52 (18.6)
512 135 (58.4) 69 (29.9) 66 (28.6) 35 (12.5) 36 (12.9) 35 (12.5)
GMTs* 252.2 185.7 190.8 65.8 56.7 60.9
* p < 0.001 group A vs. group B for all serotypes; group A: 231 children; group B: 280 elderly people.
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Europe was declared a polio-free region [2] in view of
the eradication of poliomyelitis.
The Veneto Region population enrolled in the study
globally revealed a good level of immunity against po-
liomyelitis. The younger group (A) had significantly
higher GMTs than the elderly people (group B), judging
from the time-related decline in antibody titer since ex-
posure to wild or vaccine strains of poliovirus [11, 12].
A good natural immunity to the three poliovirus types
was revealed among the elderly, even over 89 years
old: the majority of the subjects had high GMTs, prob-
ably due to their repeated exposure to poliovirus
throughout their lives, initially to the wild type and
subsequently to vaccine-derived polio virus (VDPV).
As expected, immune levels to poliovirus 1 and 2 in-
duced by OPV remain fairly stable after an initial de-
crease during the early years after vaccination, whereas
the drop in antibody to poliovirus 3 is more marked [13].
Massive vaccination with OPV has been effective in
protecting the newborn and also a natural booster
reaching people who had been immunized a long time
before, or had never been immunized with vaccine
strains. Today the indigenous population reveals an ex-
cellent protection against poliovirus infection. IPV im-
munization is currently used in our polio-free country
to avoid even the remote possibility of circulating VD-
PV and retromutated PV.
Specific immunological surveillance and/or far-reach-
ing vaccination campaigns, as the case may be, should
be implemented or maintained in immigrants, foreign
workers and adopted children coming from developing
countries in order to prevent any risk of the wild virus
reappearing and inducing polio paralysis, to keep Italy
polio-free until polio eradication has been unequivocal-
ly achieved worldwide.
The world now has a good chance of putting a stop to
the transmission of wild poliovirus, because wild po-
liovirus transmission is confined to a limited number of
polio ‘hot-spots’ in very few countries.
There are still poliomyelitis outbreaks [9] in some
countries, however, indicating that wild strains of PV
may circulate. The outbreak in the Netherlands in the
winter of 1992-93 [7] goes to show that wild strains
may be brought into polio-free areas and can lead to
symptomatic infection in communities with no herd
immunity.
Up until such a time when polio as been eradicated suc-
cessfully, a non-immune population cluster may repre-
sent a reservoir in which poliovirus can multiply, possi-
bly infecting non-immune subjects outside the cluster.
As long as endemic areas continue to exist, it will be
necessary (even in areas declared polio-free) to contin-
ue to routinely vaccinate against polio and screen the
population to check the immunity state of both indige-
nous and immigrant populations [6, 14, 15].
Conclusions
Antibody levels indicate a good protection against po-
liomyelitis in the population considered, but until polio
has been eradicated, high levels of immunity against
the three polio strains must be maintained because of
the risk of PV being imported from non polio-free ar-
eas (i.e. due to people travelling in endemic areas, im-
migration, international adoptions, etc.).
Tab. II. Neutralizing antibody GMTs according to gender, group and type of poliovirus.
gender group A group B
(n = 231) (n = 280)
poliovirus poliovirus
type 1 type 2 type 3 type 1 type 2 Type 3
males 274.2 188.9 195.6 54.9 70.2 80.1
females 229.9 182.2 185.6 69.7 52.9 55.8
total 252.2 185.7 190.8 65.8 56.7 60.9
Fig. 1 - Poliovirus neutralizing antibodies: GMTs according to age
group and type of poliovirus
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